Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers

ConclusionRegorafenib-associated AEs are more common at an initiating dose of 160 mg. Considering that the efficacy depends on the dosage, 120 mg might be a better choice for mCRC and GIST patients; further studies are needed to validate the results of our analysis. Further prompt identification and management of AEs are required to help the patients continue with drug therapy .

http://link.springer.com/10.1007/s12325-019-01013-5

Source: Advances in Therapy - June 16, 2019 Category: Drugs & Pharmacology Source Type: research